SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Supernus Pharmaceuticals, Inc.

SG&A Efficiency: AstraZeneca vs. Supernus Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, AstraZeneca PLC and Supernus Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenditures. AstraZeneca, a global leader, has seen its SG&A expenses grow by approximately 35% from 2014 to 2023, peaking in 2022. This reflects its expansive global operations and strategic investments. In contrast, Supernus Pharmaceuticals, a smaller player, has experienced a staggering 364% increase in SG&A expenses over the same period, indicating aggressive growth and market penetration strategies. While AstraZeneca's expenses are significantly higher, Supernus's rapid increase highlights its dynamic approach in a competitive market. This analysis provides a window into how these companies allocate resources to maintain and expand their market presence.